MR studies assessing effects of lowering Lp(a) levels on CHD and stroke subtypes can inform the design and conduct of randomized trials8,9,12,13,50–52 where the primary outcomes are restricted to major coronary events for some trials, but others involve a composite of major coronary events, stroke, and other vascular events. This evidence concerns the gene LPA and stroke disorder.